The addition of PD-1 blockade might enhance the efficacy of CAR T cells against brain tumors, yet it is currently unknown whether systemically administered PD-1 antibodies can achieve sufficient concentrations in the central nervous system to potentiate locoregionally delivered T-cell therapies. This evidence concerns the gene PDCD1 and brain neoplasm.